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ity and morbidity in the world, and there remains an urgent
need to develop long-lasting therapies to treat CRC and prevent
recurrence in patients. Oncolytic virus therapy (OVT) has
demonstrated remarkable efficacy in a number of different
cancer models. Here, we report a novel vaccinia virus (VV)-
based OVT for treatment of CRC. The novel VV, based
on the recently reported novel VVLDTKDN1L virus, was
armed with the pleiotropic cytokine interleukin-21 (IL-21) to
enhance anti-tumor immune responses stimulated after viral
infection of tumor cells. Compared with an unarmed virus,
VVLDTKDN1L-mIL-21 had a superior anti-tumor efficacy in
murine CMT93 subcutaneous CRC models in vivo, mediated
mainly by CD8+ T cells. Treatment resulted in development
of long-term immunity against CMT93 tumor cells, as evi-
denced by prevention of disease recurrence. These results
demonstrate that VVLDTKDN1L-mIL-21 is a promising ther-
apeutic agent for treatment of CRC.Received 17 May 2020; accepted 11 November 2020;
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Colorectal cancer (CRC) is the third most commonly diagnosed ma-
lignancy and the fourth leading cause of cancer death worldwide,1
with nearly two million new cases and one million fatalities reported
in 2018.2 Recent decades have seen a significant increase in the inci-
dence of CRC, and the global burden of CRC is expected to increase
by 60% to more than 2.2 million new cases and 1.1 million deaths by
2030.3 Common treatments of CRC include local surgical excision,
preoperative radiotherapy, extensive surgery for metastatic diseases,
palliative chemotherapy, and immunotherapy.4 These treatments
have limited impacts on the cure rate and long-term survival, espe-
cially for metastatic patients, and the 5-year survival rate for patients
with metastatic CRC remains very poor at approximately 12%.5,6
Development of new strategies to treat CRC are therefore imperative.
The recent success of cancer immunotherapy has demonstrated the
powerful ability of the immune system to detect and eradicate tumors,
inspiring scientists to explore new approaches to induce anti-tumorMolecular Therapy: Oncolytics Vol. 20 March 2021 ª 2
This is an open access article under the CC BY-NCimmune responses. Oncolytic virus therapy (OVT) involves the use
of tumor-targeted, replication-competent viruses to directly lyse tu-
mor cells and promote a proinflammatory immune environment
that supports the development of anti-tumor immune responses.7 Se-
lective tumor cell killing is a significant advantage of OVT over other
traditional therapies, including chemotherapy and radiotherapy,
which are highly toxic due to their ubiquitous targeting of replicating
cells. Anti-tumor immune responses induced byOVT have direct, tar-
geted efficacy on primary tumors but also induce immune surveillance
mechanisms that can clear metastatic tumors and prevent local tumor
recurrence.8 In 2015, the US Food and Drug Administration (FDA)
recognized the potential of OVT as a potent therapeutic option and
approved the gene-modified oncolytic herpes simplex virus (HSV),
Talimogene Laherparepvec (T-VEC), for use in advanced melanoma
patients, the first OVT to be approved in the United States.9
Vaccinia virus (VV), used extensively during the 1900s as the success-
ful smallpox vaccine, has many features that suggests it as one of the
most promising viruses for development of OVT,10 including a lack
of requirement for a specific surface receptor,11,12 the ability to repli-
cate in hypoxic environments,13 induction of immunogenic cell death
(ICD) pathways,10 an ability to induce vascular collapse within the tu-
mor microenvironment (TME),14,15 a large capacity for insertion of
exogenous genes, and a long-standing safety profile.16 Several wild-
type and genetically engineered VVs have been tested in preclinical
and clinical trials with encouraging results.10,17 The engineered west-
ern reserve (WR) strain of VVwith deletions of both thymidine kinase
(TK) and vaccinia growth factor genes (known as WRDD) is a
commonly used viral strain with strong tumor selectivity and reduced
toxicity conferred via the gene deletions but with effective anti-tumor
potency inmany tumor cell types.18We have evaluated the anti-tumor
potency andbio-distribution of differentVVstrains in vitro and in vivo020 Zhengzhou University and Queen Mary University of London. 71
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cer-selective replication in human cancer cell lines and superior anti-
tumor potency using an in vivo colon carcinoma model compared to
WRDD.19 For tumor specificity, the TK gene of VV is commonly
deleted in VV backbones (named VVLDTK). TK is required for viral
DNA synthesis, rendering the virus replication incompetent in
healthy, nondividing cells, where host cell TK is absent, and targeting
replication to tumor tissues in which cellular TK, available during host
DNA synthesis, can be hijacked by the infecting virus.20,21 We have
recently reported that an additional deletion of the VV 13.8-kDa
N1L protein, a neurovirulence factor,22 can further increase the safety
profile of the virus (named VVLDTKDN1L) and enhance anti-tumor
immune responses, particularly adaptive CD8+ T cell and innate nat-
ural killer (NK) cell responses, consequent to viral infection, resulting
in superior anti-tumor efficacy of VVLDTKDN1L compared to
VVLDTK in a number of in vivo murine and hamster models of
cancer.23
Whereas OVT has shown great potential, research and clinical
experience has demonstrated that the use of viral agents alone is insuf-
ficient to achieve clinically meaningful responses. Powerful combina-
tion therapies are therefore sought, and VV has the necessary capacity
for incorporation of transgenes to selectively deliver additional thera-
peutic agents to the tumor.24 Interleukin-21 (IL-21) presents as a good
candidate for delivery in combination with VV, as it is a potent inducer
of T cell activation in vivo25,26 and can inhibit the development of sup-
pressive Foxp3+regulatory T (Treg) cells;27 induce maturation, activa-
tion, and cytolytic potential of natural killer (NK) and NKT (natural
killer T) cells;28,29 promote B cell production of tumor-specific immu-
noglobulin G (IgG);30 and inhibit angiogenesis by reducing expression
of vascular endothelial growth factor receptor 1 (VEGFR1) and tyro-
sine kinase with immunoglobulin-like and EGF-like domains 1(TIE1)
in endothelial cells.31 Significantly, there have been no reported
adverse effects, even when administered at high doses.31 Despite its po-
tential, the anti-tumor efficacy of IL-21 as a monotherapy appears
limited in early clinical trials.32 Recently, an oncolytic adenovirus
armed with IL-21 (Ad-CCL21-IL-21) demonstrated activity and the
induction of tumor-specific cytotoxicity of cytotoxic T lymphocytes
(CTLs) to telomerase reverse transcriptase promoter (TERT)-positive
tumor cells in vitro.33 Thus, we hypothesized that the potential of IL-21
could be more fully realized by the combination of IL-21 immuno-
therapy with our virotherapeutic regime.
Here, we demonstrate that VVLDTKDN1L, armed with IL-21
(named VVLDTKDN1L-mIL-21) is an effective anti-tumor agent
using in vivo murine models of CRC, inducing robust adaptive
T cell responses that can eliminate primary tumors and induce devel-
opment of anti-tumor immunity to prevent tumor recurrence.
RESULTS
VVLDTKDN1L-mIL-21 treatment improves survival in a murine
CRC tumor model
VVLDTKDN1L-mIL-21 was constructed using CRISPR-Cas9-
based homologous recombination to insert the IL-21 gene driven72 Molecular Therapy: Oncolytics Vol. 20 March 2021by the H5 promoter into the N1L region of the Lister strain VV
genome as recently described.34,35 To determine the biological
characteristics of VVLDTKDN1L-mIL-21 in vitro, cytotoxicity
and replication of the virus were compared to the unarmed virus
(VVLDTKDN1L-Red Fluorescent Protein (RFP)) in the CRC cell
lines CMT93 and CT26. CMT93 cells supported effective replica-
tion of VVLDTKDN1L-RFP and VVLDTKDN1L-mIL-21 (Fig-
ure 1A). CT26 cells supported replication of VVLDTKDN1L-RFP
to high levels, yet the replication of VVLDTKDN1L-mIL-21
remains at relatively low levels and peaked at about 40 plaque-
forming units (PFUs)/cell at 72 h postinfection (Figure 1A). The
cytotoxicity of VVLDTKDN1L-mIL-21 was moderately attenuated
in CMT93 and CT26 cells compared to VVLDTKDN1L-RFP (Fig-
ure 1B), but the virus remained competent at cell killing in these
cell lines. Additionally, replication and cytotoxicity were tested in
a panel of lung tumor cells to determine broader application,
and all cell lines examined supported VVLDTKDN1L-mIL-21 ac-
tivity (Figure S1). To assess IL-21 expression by VVLDTKDN1L-
mIL-21, CMT93 and CT26 cells were infected with virus and the
supernatant collected for IL-21 detection by ELISA at 24 h time
points postinfection. These data demonstrate effective production
of mIL-21 at all time points in both cell lines (Figure 1C). Concen-
tration of IL-21 in the supernatant reached its peak at 48 h
(CMT93) or 72 h (CT26) postinfection and subsequently decreased
due to its short half-life, as most infected cells were lysed conse-
quent to viral infection.
For analysis of anti-tumor efficacy in vivo, CMT93 subcutaneous tu-
mors were established in immunocompetent C57BL/6 mice, and
CT26 subcutaneous tumors were established in immunocompetent
BALB/c mice. Palpable tumors were injected intratumorally (i.t.)
for 6 days (days 1, 3, 5, 7, 9, and 11) using 1  108 PFU/injection
VVLDTKDN1L-mIL-21, VVLDTKDN1L-RFP, or PBS, and the tu-
mor growth was monitored. In the CMT93 subcutaneous model,
VVLDTKDN1L-mIL-21 was significantly more effective at control-
ling tumor growth and improving survival (Figure 1D) compared to
VVLDTKDN1L-RFP, and tumors treated with VVLDTKDN1L-
mIL-21 were cleared in 85.7% (6/7) of animals compared to 42.9%
(3/7) of mice treated with VVLDTKDN1L-RFP. In the CT26 subcu-
taneous model, both VVLDTKDN1L-RFP and VVLDTKDN1L-
mIL-21 treatment retarded tumor growth significantly compared
with PBS (Figure 1E), although VVLDTKDN1L-mIL-21 did not
show significant superior antitumor efficacy compared to the control
virus.
VVLDTKDN1L-mIL-21 treatmentmodulates the TME and splenic
T cell subsets
To determine how VVLDTKDN1L-mIL-21 exerts a therapeutic ef-
fect, CD4+ and CD8+ T cells infiltrating into CMT93 subcutaneous
tumors were examined using immunohistochemistry (IHC). After
three i.t. treatments (days 1, 3, and 5), VV coat protein was
detected in tumors treated with both VVLDTKDN1L-RFP and
VVLDTKDN1L-mIL-21, and IL-21 was detected after treatment
with VVLDTKDN1L-mIL-21 (Figure 2A). Both CD4+ and CD8+
(legend on next page)
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Molecular Therapy: OncolyticsT cell infiltrations into tumors were increased after treatment with
control or IL-21-armed virus by day 7 (Figures 2A and 2B) and re-
mained elevated 14 and 20 days postinfection (Figures 2C and 2D),
although no difference in T cell infiltration was noted between the
control and IL-21-expressing virus.
Alterations of T cell subsets in spleens were also examined at each
time point following three i.t. injections of the virus. On day 7, af-
ter the first viral treatment, total CD3+ T cells from mice spleens
treated with VVLDTKDN1L-mIL-21 were significantly elevated
compared with that from mice treated with VVLDTKDN1L-RFP
or PBS (Figure 3A). This correlated with an increase in splenic
CD8+ T cells on day 7 after VVLDTKDN1L-mIL-21 treatment
compared to controls (Figure 3B); however, splenic CD4+ T cells
were significantly decreased after VVLDTKDN1L-mIL-21 treat-
ment compared with VVLDTKDN1L-RFP treatment (Figure 3C),
possibly reflecting an early mobilization of these cells to tumor
sites.
VVLDTKDN1L-mIL-21 treatment efficacy relies primarily on
CD8+ T cells
To examine in more detail the roles of different immune cells on vi-
rus-treatment efficacy of CMT93 subcutaneous tumors, CD8+ T,
CD4+ T, or NK cells were depleted by intraperitoneal (i.p.) injection
of depletion antibodies and subset depletion confirmed using flow cy-
tometry (Figure S2). Depletion of NK cells had no effect on the treat-
ment efficacy associated with VVLDTKDN1L-mIL-21, and CD4+
T cell depletion only modestly affected treatment efficacy (Figure 4).
However, depletion of CD8+ T cells had a significantly detrimental ef-
fect on the ability of VVLDTKDN1L-mIL-21 to control tumor growth
(Figure 4), demonstrating that VVLDTKDN1L-mIL-21 acts primarily
via adaptive CD8+ T cells to mediate anti-tumor effects in this model.
VVLDTKDN1L-mIL-21 treatment promotes memory T cell
formation and prevents CMT93 tumor recurrence
Central memory T cell subsets (CD8+CD44hiCD62LhiTcm) in mu-
rine spleens were analyzed by flow cytometry after 3 i.t. injections,
as above, according to gating criteria for memory T cells (Figure S3).
VVLDTKDN1L-mIL-21 significantly promoted Tcm-CD8 forma-
tion on days 14 and 20 after the first viral treatment (Figure 5A).
To determine whether these cells were able to prevent tumor recur-
rence and thus were indicative of robust anti-tumor effects, 30 days
after primary tumors were cleared by OVT, mice were rechallenged
with 1 107 CMT93 cells (twice the number of cells compared to the
primary tumor cell inoculation). At day 1 after rechallenge, the vol-
ume of tumor tissues at the inoculation site of some mice reached up
to 100 mm3, due to the injection volume requiring dissipation.Figure 1. Anti-tumor efficacy of VVLDTKDN1L-RFP and VVLDTKDN1L-mIL-21
(A) Production of infectious vaccinia virus (VV) in CMT93 cells and CT26 cells after infe
VVLDTKDN1L-RFP and VVLDTKDN1L-mIL-21 against CMT93 and CT26 cells. *p < 0.0
0.001. (D) CMT93 subcutaneous tumor volumes were decreased after i.t. treatment. *
CMT93 tumors was used to determine survival (right panel), n = 7. (E) CT26 subcutaneou
Meier analysis of treated mice bearing CT26 tumors was used to determine survival (rig
74 Molecular Therapy: Oncolytics Vol. 20 March 2021Subsequently, the tumor volume gradually decreased to complete
disappearance with the absorption of PBS used for inoculation of
tumor cells and the activation of anti-tumor immunity that
prevented the growth of inoculated cells. Both VVLDTKDN1L-
RFP- and VVLDTKDN1L-mIL-21-treated mice were able to reject
CMT93 cells after rechallenge (Figure 5B), but VVLDTKDN1L-
mIL-21-treated mice were able to reject tumors more rapidly
compared to VVLDTKDN1L-RFP-treated mice, demonstrating
that OVT strategies not only eradicate the primary tumors but
also induce long-term antitumor immunity to prevent tumor
recurrence. We further examined interferon (IFN)-g production
by splenocytes taken from treated mice. Ex vivo stimulation with
mitomycin C (MMC)-treated CMT93 cells resulted in significantly
increased IFN-g expression in virus-treated groups compared with
that from PBS-treated mice (Figure 5C), with VVLDTKDN1L-
mIL-21 treatment trending toward more powerful stimulation
of anti-tumor immunity. Restimulation with an unrelated cell
line, MMC-treated CT26 CRC, was unable to induce IFN-g
expression, demonstrating an induction of specific anti-tumor im-
munity after virus treatment. Interestingly, only treatment with
VVLDTKDN1L-mIL-21 was able to significantly induce antiviral
immunity in this model. In the context of OVT, antiviral immunity
is a double-edged sword. On the one hand, it allows for increased
tumor targeting by immune cells that recognize viral antigen on
infected tumor cells. On the other hand, this may lead to more
rapid viral clearance that reduces the ability of the virus to promote
oncolysis. Given the improved efficacy noted in vivo using
VVLDTKDN1L-mIL-21, it may be assumed that in this model,
the former consequence has a more powerful effect than the latter,
and antiviral immunity may assist in promoting tumor destruction.
DISCUSSION
OVT is widely acknowledged as a validated immunotherapeutic strat-
egy against cancer, with strong potential to act in synergy with other
immunotherapies and conventional therapies to improve clinical out-
comes via induction of anti-tumor immune responses. VV has many
inherent characteristics that make it an ideal oncolytic agent for treat-
ment of pancreatic cancer;10 however, the limited therapeutic efficacy
noted in numerous clinical trials with oncolytic VV suggests that
treatment strategies must be optimized to address these limitations,
with emphasis placed on improving strategies for overcoming the
strongly immunosuppressive TME.36–38
We have recently described a novel oncolytic VV, based on the
Lister strain backbone that we found to have the most acceptable
therapeutic index in comparison to other strains of VV, including
the commonly used WR strain, originally reported as the mostin murine subcutaneous CMT93 and CT26 models
ction at an MOI of 5 PFUs/cell. ns, not significant; ***p < 0.001. (B) Cytotoxicity of
5. (C) mIL-21 expression by VVLDTKDN1L-mIL-21 in CMT93 and CT26 cells. ***p <
*p < 0.01, ***p < 0.001 (left panel). Kaplan-Meier analysis of treated mice bearing
s tumor volumeswere decreased after i.t. treatment. ***p < 0.001 (left panel). Kaplan-
ht panel), n = 7.
Figure 2. VVLDTKDN1L-mIL-21 therapy induces
infiltration of T cells into the CMT93 tumor
(A) Representative images of immunohistochemical (IHC)
staining for CD4+ T and CD8+ T cells, coat protein of VV,
and mIL-21 in CMT93 subcutaneous tumors collected on
day 7, n = 3/time point. (B–D) CD4+ T and CD8+ T cells
were counted in five high-power fields (HPFs) from each
tumor section (200). Quantitative scores of lymphocyte
infiltration within tumors are shown. The scoring was
conducted within the subcutaneous tumor on days 7 (B),
14 (C), and 20 (D) after the first viral treatment. The extent
of positive cells was categorized into the following four
grades: 1, <15 cells/HPF; 2, 16–30 cells/HPF; 3, 31–45
cells/HPF; 4, >45 cells/HPF.
www.moleculartherapy.org
Molecular Therapy: Oncolytics Vol. 20 March 2021 75
Figure 3. T cell subsets in spleens from
VVLDTKDN1L-RFP- or VVLDTKDN1L-mIL-21-treated
mice of the CMT93 subcutaneous model
(A) CD3+ populations as a percentage of live cells in sple-
nocytes of treated mice assessed by gating on CD3+
populations. (B) CD8+ populations as a percentage of live
cells in splenocytes of treated mice assessed by gating on
CD3+CD8+ populations. (C) CD4+ populations as a per-
centage of live cells in splenocytes of treatedmice assessed
by gating on CD3+CD4+ populations. *p < 0.05, ***p <
0.001, n = 3/time point.
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Figure 4. VVLDTKDN1L-mIL-21 efficacy is mediated by CD8+ T cells in the
CMT93 subcutaneous model
CMT93 subcutaneous tumors were established in female C57BL/6 mice and
treated as described previously on days 1, 3, 5, 7, 9, and 11. The day before each
viral treatment, rat anti-mouse CD4, CD8, NK, or control monoclonal antibodies
were injected i.p. n = 7/group. Tumors were measured twice weekly. **p < 0.01,
***p < 0.001.
www.moleculartherapy.orgpotent strain of VV.18,19 Modification of tumor-specific VVL
(VVLDTK, with deletion of the viral TK gene) by removing the
N1L gene (VVLDTKDN1L) significantly enhanced both innate
and adaptive immune responses systemically and within the
TME after i.t. delivery compared to the parental VVLDTK, result-
ing in impressive anti-tumor efficacy in murine models of lung and
pancreatic cancer.23
Here, we report the biological characteristics and anti-tumor efficacy
of a novel VV armed with IL-21, VVLDTKDN1L-mIL-21, on CRC.
Despite the increase of therapeutic options available to improve prog-
nosis for CRC patients, it remains one of the most commonly diag-
nosed cancers, responsible for up to 10% of all cancer deaths yearly.
CMT93 cells, a murine CRC cell line, have a relatively low intrinsic
immunogenicity39 and as such, are not easily controlled by the im-
mune system. However, it has recently been demonstrated that infec-
tion with the oncolytic adenovirus could induce ICD pathways in
CMT93 cells, and we have shown that VV is able to induce ICD in
other tumor cell lines; thus, OVT represents a promising mechanism
by which to evoke immune responses against poorly immunogenic
tumors.40,41 Indeed, previous studies have demonstrated sensitivity
of colorectal tumor-initiating cells (TICs) to JX-594, the most clini-
cally advanced oncolytic VV—a significant finding, as TICs are gener-
ally resistant to standard therapeutic interventions.42 Here, we
demonstrated that whereas VVLDTKDN1L-RFP was able to exert
anti-tumor efficacy in the CMT93 cancer model, arming the virus
with IL-21 significantly enhanced this ability and improved long-
term survival of animals. Both viruses were able to induce CD8+and CD4+ T cell infiltration into the tumor, but the IL-21-armed virus
was able to significantly enhance effector CD8+ T cell populations
within the spleen, suggesting that IL-21 promotes a higher production
of anti-tumor effector CD8+ T cells. Indeed, depletion of CD8+ T cells,
but not CD4+ T cells or NK cells, prevented the anti-tumor effect
associated with i.t. treatment using VVLDTKDN1L-mIL-21. Rechal-
lenge experiments also demonstrated that both viruses were able to
evoke long-term immunity against CMT93 tumor cells and prevent
tumor recurrence, although addition of IL-21 to the initial treatment
resulted in a more rapid clearance of secondary tumors.
We also tested the treatment efficacy of VVLDTKDN1L-RFP and
VVLDTKDN1L-mIL-21 on the CT26 subcutaneous model; both
viruses’ treatment could retard the tumor growth, yet the treatment
efficacy on CT26 models is largely worse than that on CMT93
models. The viral therapeutic efficacy of the virus depends partly
on the virus itself, VVLDTKDN1L-mIL-21 replication is signifi-
cantly reduced, with less potency in CT26 cells compared to the con-
trol virus (Figures 1A and 1B). This may explain the efficacy result
in vivo (Figure 1E). In addition, the different genetic backgrounds
of CT26 BALB/c mice (T helper [Th]2 dominant) and CMT93
C57BL/6 mice (Th1 dominant) may also affect the immunothera-
peutic efficacy of the viruses. Tumor heterogeneity is one important
factor affecting the efficacy of tumor therapy, so it is particularly
important to advocate personalized tumor therapy. All of these war-
rant further investigations.
Together, these results describe a rationally constructed OV-based
therapeutic platform for CRC that effectively addresses many of the
shortfalls of current OV-based platforms in clinical development
and may expand the therapeutic landscape for CRC patients.
MATERIALS AND METHODS
Viruses
VVLDTKDN1L-RFP was described previously.43,44 VVLDTKDN1L-
IL-21 (containing the mouse interleukin-21, named as
VVLDTKDN1L-mIL-21e) construction was described previously.34
Cell lines
All tumor cell lines were obtained from CRUK, Clare Hall, Herts, UK.
CV1 cells derived from African monkey kidney were obtained from
the American Type Culture Collection (ATCC). CMT93, CV1,
LLC, CMT64, CMT167, and CMT170 cells were maintained in Dul-
becco’s modified Eagle’s medium (DMEM) with 10% fetal bovine
serum (FBS). CT26 cells were maintained in Roswell Park Memorial
Institute (RMPI) 1640 with 10% FBS.
Cytotoxicity assay
VV was first diluted to a multiplicity of infection (MOI) of 1,000
PFUs/cell as initial concentration and then 1:10 serial dilutions
used to infect each column of a 96-well plate to a final concentration
of 105 PFUs/cell. Tumor cells were seeded at 2  103 cells per
well in 96-well plates and separately infected with viruses 16–18 h
later. Cell survival on day 6 after viral infection was determinedMolecular Therapy: Oncolytics Vol. 20 March 2021 77
Figure 5. VVLDTKDN1L-mIL-21 promotes memory
T cell formation and prevents tumor recurrence in
the CMT93 subcutaneous model
(A) CD8+ Tcm populations as a percentage of CD8+ cells
in splenocytes of treated mice were determined using
FACS analysis (n = 9/group). *p < 0.05. (B) Mice that had
cleared tumors after i.t. treatment with VVLDTKDN1L-
RFP or VVLDTKDN1L-mIL-21 during efficacy experi-
ments were rechallenged 4 weeks later in the opposite
flank with 1  107 CMT93 cells and tumor growth
measured as done previously. VVLDTKDN1L-RFP (n = 3);
VVLDTKDN1L-mIL-21 (n = 6). **p < 0.01. (C) Splenocytes
from treated mice on day 20 after first viral treatment were
incubated for 72 h with MMC-treated CMT93 or MMC-
treated CT26, and IFN-g production in response to
stimulation was measured by ELISA. **p < 0.01.
Molecular Therapy: Oncolyticsby 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)- 2H-tetrazolium(MTS) assay (Promega), according to
the manufacturer’s instructions, and EC50 values (viral dose killing
50% of tumor cells) were calculated as previously described.45 All as-
says were performed at least three times.
Viral replication assay
Tumor cells were seeded at 2  105 cells per well in three wells of
6-well plates in medium with 10% FBS, and infected with 5 PFUs/cell78 Molecular Therapy: Oncolytics Vol. 20 March 2021of VVLDTKDN1L-mIL-21 or VVLDTKDN1L-
RFP in media with 2% FBS 16–18 h later. Sam-
ples were collected at 24-h intervals up to 96 h
after infection, freeze thawed three times, and
titrated on CV1 cells to determine the 50% tis-
sue culture infective dose (TCID50), as previ-
ously described.46
In vivo animal studies
All animal studies carried out were approved by
the Animal Welfare and Research Ethics Com-
mittee of Zhengzhou University (Zhengzhou,
China).
Treatment efficacy experiments
5  106 CMT93 or CT26 cells were implanted
subcutaneously into the right flank of female,
5- to 6-week-old C57BL/6 or BALB/c (for
CT26 models) mice. When tumors reached
100 mm3, mice were divided into 3 groups
by matched tumor size to receive six i.t. injec-
tions of 1  108 PFU/100 mL VVLDTKDN1L-
mIL-21 or VVLDTKDN1L-RFP for treatment
or 100 mL PBS for control. Solutions were in-
jected slowly into established tumors to allow
injected solution to dissipate evenly during
the injection process. Tumor growth was






where w is width, and l is length.
Tumor growth curves were terminated upon the death of the first an-
imal in each group. Kaplan-Meier survival plots generated that the
www.moleculartherapy.orgexperimental animals were recorded as death when the tumor volume
reached 1,500 mm3.
Mechanism experiments
5  106 CMT93 cells were implanted subcutaneously into the right
flank of female, 5- to 6-week-old C57BL/6mice.When tumors reached
150 mm3, mice were randomly divided into three groups by
matched tumor size to receive i.t. injections of 1  108 PFU/
100 mLVVLDTKDN1L-mIL-21 or VVLDTKDN1L-RFP for treatment
or PBS for control on days 1, 3, and 5. On days 7, 14, and 20, subcu-
taneous tumors, spleens, and lymph nodes were collected from three
mice in each group for further investigation, including immunohisto-
chemistry (IHC), fluorescence-activated cell sorting (FACS) analysis,
and IFN-g release assay.
IHC
CMT93 subcutaneous tumors were collected, snap frozen, and stored
at80C. Frozen tissuewas processed for IHCanalysis ofVVcoat pro-
tein (1:50 rabbit anti-VV coat protein polyclonal antibody;MorphoSys
UK), mIL-21 (Abcam; ab5978) secretion, CD4+ T (BioLegend;
100402), and CD8+ T (BioLegend; 100702) cell infiltration.
IFN-g release assay
Spleens were collected from a CMT93 subcutaneous mice model and
maintained in T cell culture medium (RPMI medium, 10% FBS, 1%
penicillin-streptomycin, and 1% sodium pyruvate), and cells were
separated using a 70-mm cell strainer. Red blood cells were lysed using
red blood cell (RBC) lysis buffer (Sigma-Aldrich) and cells resus-
pended in complete T cell medium. 5  105/well/100 mL splenocytes
were seeded into each well of a 96-well plate in triplicate. Cells were
restimulated with 5  105 MMC-treated CMT93 cells or 5  105
MMC-treated CT26 cells. Restimulated splenocytes were incubated
for 72 h at 37C, and the supernatant was collected for ELISA to
quantify IFN-g release.
mIL-21 and IFN-g ELISA
mIL-21 or IFN-g protein levels were quantified using IL-21 mouse
uncoated ELISA (Invitrogen; 88-8210-88) or mouse IFN-g uncoated
ELISA (Invitrogen; 88-7314-88), according to the manufacturer’s in-
structions. Data (pg/mL) were normalized to the IL-21 standard or
IFN-g standard provided by the kit.
FACS analysis
Spleens fromaCMT93 subcutaneousmicemodelwere collected, com-
bined with T cell culture medium, and then pushed through a 70-mm
cell strainer to create a single-cell suspension. Cells were centrifuged
and the pellet incubated in 5 mL RBC lysis buffer (Sigma-Aldrich).
Splenocytes (1  106) were prepared and stained with monoclonal
antibody (mAb) against mouse CD3 conjugated with phycoerythrin
(PE )(eBioscience), mAb against mouse CD4 conjugated with fluores-
cein isothiocyanate (FITC; eBioscience), mAb against mouse CD8
conjugated with allophycocyanin (APC) (eBioscience), mAb against
mouse CD44 conjugated with BV421 (eBioscience), and mAb against
mouse CD62L conjugated with PerCP-Cyanine5.5 (eBioscience).Cells were examined using a BD FACSAria III flow cytometer, and
data were analyzed using Diva software.
Immune cell subset depletion in vivo
5  106 CMT93 cells were seeded subcutaneously into 5- to 6-week-
old C57BL/6 mice. When tumors reached 100 mm3, mice were
randomly divided into 5 groups by matched tumor size to receive
i.t. injections of 1  108 PFU/100 mLVVLDTKDN1L-mIL-21 twice
a week. Depletion mAbs against mouse NK (antibody clone
PK136), CD4 (antibody clone GK7.5), CD8 (antibody clone
TIB210), and control Ig (mouse anti-KLH mAb) were administered
i.p. the day before virotherapy in 200 mL PBS at 200 mg/injection.
Injections were continued twice weekly for the duration of the exper-
iment, and FACS analysis was used to confirm depletion. Tumor
volumes were measured twice a week as described above. Seven
mice per group were used.
Rechallenge of tumor-free animals
The C57BL/6 mice that underwent complete subcutaneous
tumor regression following VVLDTKDN1L-mIL-21 (n = 6) or
VVLDTKDN1L-RFP (n = 3) treatment were rechallenged with
1  107 CMT93 cells (twice the number of cells compared to the pri-
mary tumor cell inoculation) after primary tumors had been cleared
for 30 days. Tumor volumes were measured twice weekly.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.0. The re-
sults were represented as mean ± SD. Comparison between groups
was performed using t test, one-way ANOVA, two-way ANOVA,
or Kaplan-Meier survival analysis. p <0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.
1016/j.omto.2020.11.002.
ACKNOWLEDGMENTS
This project was supported by the National Key R&D Program of
China (2016YFE0200800), the Nature Sciences Foundation of China
(81771776 and U1704282), Pancreatic Cancer UK (2010/YW), and
The MRC (MR/M015696/1).
AUTHOR CONTRIBUTIONS
Y.W. conceived and designed the experiments. N.W., J.W., Z.Z., H.C.,
W.Y., and Y.C. performed the experiments. N.W. and J.W. analyzed
the data. N.W. drafted the manuscript. L.S.C.D. and Y.W. interpreted
the data and finalized the manuscript.
DECLARATION OF INTERESTS
The authors declare no competing interests.
REFERENCES
1. Buccafusca, G., Proserpio, I., Tralongo, A.C., Rametta Giuliano, S., and Tralongo, P.
(2019). Early colorectal cancer: diagnosis, treatment and survivorship care. Crit. Rev.
Oncol. Hematol. 136, 20–30.Molecular Therapy: Oncolytics Vol. 20 March 2021 79
Molecular Therapy: Oncolytics2. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., and Jemal, A. (2018).
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424.
3. Arnold, M., Sierra, M.S., Laversanne, M., Soerjomataram, I., Jemal, A., and Bray, F.
(2017). Global patterns and trends in colorectal cancer incidence and mortality.
Gut 66, 683–691.
4. Dekker, E., Tanis, P.J., Vleugels, J.L.A., Kasi, P.M., and Wallace, M.B. (2019).
Colorectal cancer. Lancet 394, 1467–1480.
5. Kuipers, E.J., Grady, W.M., Lieberman, D., Seufferlein, T., Sung, J.J., Boelens, P.G.,
van de Velde, C.J., and Watanabe, T. (2015). Colorectal cancer. Nat. Rev. Dis.
Primers 1, 15065.
6. Siegel, R.L., Miller, K.D., and Jemal, A. (2016). Cancer statistics, 2016. CA Cancer J.
Clin. 66, 7–30.
7. Chiocca, E.A., and Rabkin, S.D. (2014). Oncolytic viruses and their application to
cancer immunotherapy. Cancer Immunol. Res. 2, 295–300.
8. Marelli, G., Howells, A., Lemoine, N.R., and Wang, Y. (2018). Oncolytic Viral
Therapy and the Immune System: A Double-Edged Sword Against Cancer. Front.
Immunol. 9, 866.
9. Ott, P.A., and Hodi, F.S. (2016). Talimogene Laherparepvec for the Treatment of
Advanced Melanoma. Clin. Cancer Res. 22, 3127–3131.
10. Guo, Z.S., Lu, B., Guo, Z., Giehl, E., Feist, M., Dai, E., Liu, W., Storkus, W.J., He, Y.,
Liu, Z., and Bartlett, D.L. (2019). Vaccinia virus-mediated cancer immunotherapy:
cancer vaccines and oncolytics. J. Immunother. Cancer 7, 6.
11. Mercer, J., and Helenius, A. (2008). Vaccinia virus uses macropinocytosis and
apoptotic mimicry to enter host cells. Science 320, 531–535.
12. Moss, B. (2006). Poxvirus entry and membrane fusion. Virology 344, 48–54.
13. Hiley, C.T., Yuan, M., Lemoine, N.R., and Wang, Y. (2010). Lister strain vaccinia vi-
rus, a potential therapeutic vector targeting hypoxic tumours. Gene Ther. 17,
281–287.
14. Breitbach, C.J., Paterson, J.M., Lemay, C.G., Falls, T.J., McGuire, A., Parato, K.A.,
Stojdl, D.F., Daneshmand, M., Speth, K., Kirn, D., et al. (2007). Targeted inflamma-
tion during oncolytic virus therapy severely compromises tumor blood flow. Mol.
Ther. 15, 1686–1693.
15. Kirn, D.H., Wang, Y., Liang, W., Contag, C.H., and Thorne, S.H. (2008). Enhancing
poxvirus oncolytic effects through increased spread and immune evasion. Cancer
Res. 68, 2071–2075.
16. Al Yaghchi, C., Zhang, Z., Alusi, G., Lemoine, N.R., and Wang, Y. (2015). Vaccinia
virus, a promising new therapeutic agent for pancreatic cancer. Immunotherapy 7,
1249–1258.
17. Haddad, D. (2017). Genetically Engineered Vaccinia Viruses As Agents for Cancer
Treatment, Imaging, and Transgene Delivery. Front. Oncol. 7, 96.
18. McCart, J.A., Ward, J.M., Lee, J., Hu, Y., Alexander, H.R., Libutti, S.K., Moss, B., and
Bartlett, D.L. (2001). Systemic cancer therapy with a tumor-selective vaccinia virus
mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 61,
8751–8757.
19. Hughes, J., Wang, P., Alusi, G., Shi, H., Chu, Y., Wang, J., Bhakta, V., McNeish, I.,
McCart, A., Lemoine, N.R., and Wang, Y. (2015). Lister strain vaccinia virus with
thymidine kinase gene deletion is a tractable platform for development of a new gen-
eration of oncolytic virus. Gene Ther. 22, 476–484.
20. Buller, R.M., Smith, G.L., Cremer, K., Notkins, A.L., and Moss, B. (1985). Decreased
virulence of recombinant vaccinia virus expression vectors is associated with a thymi-
dine kinase-negative phenotype. Nature 317, 813–815.
21. Whitman, E.D., Tsung, K., Paxson, J., and Norton, J.A. (1994). In vitro and
in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery
116, 183–188.
22. Kotwal, G.J., and Moss, B. (1989). Vaccinia virus encodes two proteins that are struc-
turally related to members of the plasma serine protease inhibitor superfamily.
J. Virol. 63, 600–606.
23. Ahmed, J., Chard, L.S., Yuan, M., Wang, J., Howells, A., Li, Y., Li, H., Zhang, Z., Lu, S.,
Gao, D., et al. (2020). A new oncolytic Vacciniavirus augments antitumor immune80 Molecular Therapy: Oncolytics Vol. 20 March 2021responses to prevent tumor recurrence and metastasis after surgery.
J. Immunother. Cancer 8, e000415.
24. Sampath, P., and Thorne, S.H. (2013). Arming viruses in multi-mechanistic oncolytic
viral therapy: current research and future developments, with emphasis on poxvi-
ruses. Oncolytic Virother. 3, 1–9.
25. Li, Y., Bleakley, M., and Yee, C. (2005). IL-21 influences the frequency,
phenotype, and affinity of the antigen-specific CD8 T cell response. J. Immunol.
175, 2261–2269.
26. Moroz, A., Eppolito, C., Li, Q., Tao, J., Clegg, C.H., and Shrikant, P.A. (2004). IL-21
enhances and sustains CD8+ T cell responses to achieve durable tumor immunity:
comparative evaluation of IL-2, IL-15, and IL-21. J. Immunol. 173, 900–909.
27. Nurieva, R., Yang, X.O., Martinez, G., Zhang, Y., Panopoulos, A.D., Ma, L., Schluns,
K., Tian, Q., Watowich, S.S., Jetten, A.M., and Dong, C. (2007). Essential
autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature
448, 480–483.
28. Brady, J., Hayakawa, Y., Smyth, M.J., and Nutt, S.L. (2004). IL-21 induces the func-
tional maturation of murine NK cells. J. Immunol. 172, 2048–2058.
29. Coquet, J.M., Kyparissoudis, K., Pellicci, D.G., Besra, G., Berzins, S.P., Smyth, M.J.,
and Godfrey, D.I. (2007). IL-21 is produced by NKT cells and modulates NKT cell
activation and cytokine production. J. Immunol. 178, 2827–2834.
30. Nakano, H., Kishida, T., Asada, H., Shin-Ya, M., Shinomiya, T., Imanishi, J., Shimada,
T., Nakai, S., Takeuchi, M., Hisa, Y., and Mazda, O. (2006). Interleukin-21 triggers
both cellular and humoral immune responses leading to therapeutic antitumor effects
against head and neck squamous cell carcinoma. J. Gene Med. 8, 90–99.
31. Castermans, K., Tabruyn, S.P., Zeng, R., van Beijnum, J.R., Eppolito, C., Leonard,
W.J., Shrikant, P.A., and Griffioen, A.W. (2008). Angiostatic activity of the antitumor
cytokine interleukin-21. Blood 112, 4940–4947.
32. Thompson, J.A., Curti, B.D., Redman, B.G., Bhatia, S., Weber, J.S., Agarwala, S.S.,
Sievers, E.L., Hughes, S.D., DeVries, T.A., and Hausman, D.F. (2008). Phase I study
of recombinant interleukin-21 in patients with metastatic melanoma and renal cell
carcinoma. J. Clin. Oncol. 26, 2034–2039.
33. Li, Y., Li, Y.-F., Si, C.-Z., Zhu, Y.-H., Jin, Y., Zhu, T.-T., Liu, M.-Y., and Liu, G.-Y.
(2016). CCL21/IL21-armed oncolytic adenovirus enhances antitumor activity against
TERT-positive tumor cells. Virus Res. 220, 172–178.
34. Yuan, M., Gao, X., Chard, L.S., Ali, Z., Ahmed, J., Li, Y., Liu, P., Lemoine, N.R., and
Wang, Y. (2015). A marker-free system for highly efficient construction of vaccinia
virus vectors using CRISPR Cas9. Mol. Ther. Methods Clin. Dev. 2, 15035.
35. Yuan, M., Wang, P., Chard, L.S., Lemoine, N.R., and Wang, Y. (2016). A Simple and
Efficient Approach to Construct Mutant Vaccinia Virus Vectors. J. Vis. Exp. 30,
54171.
36. Achard, C., Surendran, A., Wedge, M.E., Ungerechts, G., Bell, J., and Ilkow, C.S.
(2018). Lighting a Fire in the Tumor Microenvironment Using Oncolytic
Immunotherapy. EBioMedicine 31, 17–24.
37. Kaufman, H.L., Kohlhapp, F.J., and Zloza, A. (2015). Oncolytic viruses: a new class of
immunotherapy drugs. Nat. Rev. Drug Discov. 14, 642–662.
38. Raja, J., Ludwig, J.M., Gettinger, S.N., Schalper, K.A., and Kim, H.S. (2018). Oncolytic
virus immunotherapy: future prospects for oncology. J. Immunother. Cancer 6, 140.
39. Chong, H., Todryk, S., Hutchinson, G., Hart, I.R., and Vile, R.G. (1998). Tumour cell
expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macro-
phage colony-stimulating factor induces a local antitumour response and may
generate systemic protective immunity. Gene Ther. 5, 223–232.
40. Yamano, T., Kubo, S., Fukumoto, M., Yano, A., Mawatari-Furukawa, Y., Okamura,
H., and Tomita, N. (2016). Whole cell vaccination using immunogenic cell death
by an oncolytic adenovirus is effective against a colorectal cancer model. Mol.
Ther. Oncolytics 3, 16031.
41. Lu, S., Zhang, Z., Du, P., Chard, L.S., Yan, W., El Khouri, M., Wang, Z., Zhang, Z.,
Chu, Y., Gao, D., et al. (2020). A Virus-Infected, Reprogrammed Somatic
Cell-Derived Tumor Cell (VIReST) Vaccination Regime Can Prevent Initiation
and Progression of Pancreatic Cancer. Clin. Cancer Res. 26, 465–476.
42. Conrad, S.J., and Essani, K. (2014). Oncoselectivity in Oncolytic Viruses against
Colorectal Cancer. J. Cancer Ther. 5, 1153–1174.
www.moleculartherapy.org43. Yuan, M., Zhang, W., Wang, J., Al Yaghchi, C., Ahmed, J., Chard, L., Lemoine, N.R.,
and Wang, Y. (2015). Efficiently editing the vaccinia virus genome by using the
CRISPR-Cas9 system. J. Virol. 89, 5176–5179.
44. Dénes, B., Yu, J., Fodor, N., Takátsy, Z., Fodor, I., and Langridge, W.H. (2006).
Suppression of hyperglycemia in NOD mice after inoculation with recombinant
vaccinia viruses. Mol. Biotechnol. 34, 317–327.45. Wang, Y., Hallden, G., Hill, R., Anand, A., Liu, T.-C., Francis, J., Brooks, G., Lemoine,
N., and Kirn, D. (2003). E3 gene manipulations affect oncolytic adenovirus activity in
immunocompetent tumor models. Nat. Biotechnol. 21, 1328–1335.
46. Reed, L.J., and Muench, H. (1938). A simple method of estimating fifty percent end-
points. Am. J. Hyg. 27, 493–497.Molecular Therapy: Oncolytics Vol. 20 March 2021 81
